Table 5 Comparison of survival on CRRT by principal diagnosis, weight, CRRT indication, and immune status between study eras and shown over the 10Â year study period
|  | 2004–2008 | 2009–2013 | 2004–2013 |
|---|---|---|---|
Survivor n (%) | Survivor n (%) | Survivor n (%) | |
Principal Diagnosis Category | |||
 Cardiac | 7 (54%) | 3 (27%) | 10 (42%) |
 Renal | 4 (44%) | 14 (74%) | 18 (64%) |
 Liver | 6 (32%) | 17 (46%) | 23 (41%) |
 Hematology/Oncology a | 10 (56%) | 3 (18%) | 13 (37%) |
 Bone marrow transplant | 3 (17%) | 5 (33%) | 8 (24%) |
 Pulmonary | 4 (36%) | 2 (50%) | 6 (40%) |
 Inborn error of metabolism | 5 (100%) | 7 (70%) | 12 (80%) |
 Sepsis | 3 (30%) | 2 (40%) | 5 (33%) |
 Neonates | 8 (80%) | 8 (62%) | 16 (70%) |
 Other b | 10 (63%) | 10 (77%) | 20 (69%) |
Weight | |||
 0-10 kg | 9 (35%) | 19 (50%) | 28 (44%) |
 10-25 kg | 13 (45%) | 22 (56%) | 35 (51%) |
 25-50 kg | 17 (49%) | 13 (39%) | 30 (44%) |
 > 50 kg | 21 (54%) | 17 (50%) | 38 (52%) |
Indications for CRRT | |||
 Fluid overload | 31 (42%) | 35 (49%) | 66 (46%) |
 Fluid overload & electrolyte management | 12 (43%) | 17 (41%) | 29 (41%) |
 Prevent fluid overload/provide nutrition | 3 (50%) | 2 (67%) | 5 (56%) |
 Electrolyte management | 4 (57%) | 4 (44%) | 8 (50%) |
 Other c | 10 (71%) | 13 (68%) | 23 (70%) |
Days on CRRT | |||
 1 day | 8 (47%) | 5 (55%) | 12 (50%) |
 2–7 days | 24 (42%) | 34 (45%) | 58 (44%) |
 8–14 days | 18 (50%) | 12 (36%) | 30 (43%) |
 15–21 days | 10 (53%) | 11 (48%) | 21 (50%) |
 22–28 days | 1 (17%) | 7 (50%) | 8 (40%) |
 > 28 days | 3 (25%) | 7 (50%) | 10 (38%) |
Immune Status | |||
 Solid organ transplant | 11 (44%) | 17 (52%) | 28 (48%) |
 Bone marrow transplant | 5 (29%) | 5 (36%) | 10 (32%) |
 Other immunocompromised | 12 (48%) | 11 (42%) | 23 (45%) |
 Not immunocompromised | 32 (52%) | 38 (54%) | 70 (53%) |